QuartzBio Team, Author at QuartzBio

About QuartzBio Team

This author has not written his bio yet.
But we are proud to say that QuartzBio Team contributed 72 entries already.

Entries by QuartzBio Team

Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients

March 5, 2021 — Applying algorithms to interconnected biomarker and clinical data can yield scientific insights, not only into therapeutic mechanisms, but also into predicting long-term response to treatment. In a collaboration with investigators at Janssen, the QuartzBio team sought to identify genetic markers correlated with protection against chronic hepatitis B early relapse in patients […]

Join QuartzBio at the SCOPE 2021 Virtual Conference for Clinical Operations Executives

Join QuartzBio at the SCOPE 2021 virtual conference for the “Clinical Biomarkers Operations and Innovation” track on March 2. PRESENTATION: “Centralizing PK, Clinical, and Exploratory Biospecimen Data to Streamline Trial Operations & Intelligence” Clinical samples are frequently a logistical headache – managed too often in Excel files that are time-consuming to update, and quickly fall […]

Translational Intelligence: On-Study Applications of Machine Learning to Integrated Biomarker and Clinical Data

February 12, 2021 — Integrating clinical and biomarker data enables both operational insights as well as scientific insights that can help teams make clinical trial decisions on-study. Our last article defined the synthesis of these insights as translational intelligence, with the potential to illuminate key insights in drug development just as business intelligence is used […]

Webinar On Demand: Critical On-Study Biomarker KPIs for Modern Trials

Watch on Demand: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams Duration: 45 minutes Sign up to watch the webinar on demand: You will learn how to: Abstract of the Webinar Today’s clinical trials have global footprints to reach targeted patient populations and rely on specialty labs running complex assays to assess safety, […]

Translational Intelligence: Unlocking Insights from Expansive Biomarker Data

February 3, 2021 — In this brief, we explore Translational Intelligence – that is, navigating the vast biomarker data ecosystem to quickly uncover insights that would be missed by visual inspection alone, and which enable translational teams to focus on the right pathways, biological mechanisms, and / or patient populations.

Precision Medicine Group Secures Major Investment from Blackstone

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, […]

Enabling Translational Intelligence to Rapidly Surface On-study Operational and Scientific Insights

November 12, 2020 — In this article, QuartzBio Managing Director Scott Marshall discusses critical steps to integrating clinical, PK, and exploratory data on-study to advance operational and translational insights (without all the manual effort that has become all too common). With our experience working across dozens of clients and hundreds of studies, we’ve identified four […]

Centralizing PK, Clinical, and Exploratory Data to Advance Biomarker Operations and Translational Intelligence

September 24, 2020 — The COVID-19 pandemic has forced clinical trial stakeholders to rethink the paradigm as sponsors adapt to site restrictions, remote monitoring, and updated regulatory guidance. This is especially true in precision medicine programs, which have developed global footprints in order to reach targeted patient populations and rely on specialty labs running complex […]

What does precision medicine actually mean and how can AI and ML impact it?

September 21, 2020 — What does precision medicine actually mean and how can AI and ML impact it? QuartzBio’s Renee Deehan and panelists explore AI and ML’s impact on precision medicine and what the industry needs to do to prepare for it, tackle challenges as they evolve and develop appropriate solutions. Learn More

The Importance of Biomarker Data Management

August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to […]